Home » Topics » Disease categories and therapies » Infection

Infection
RSS

Abbott initiates phase II trials with ABT-606

Oct. 7, 1998

Spotlight on antifungal agents for treating aspergillosis

Oct. 7, 1998

Gatifloxacin highlighted at ICAAC as an effective new treatment for pneumonia

Oct. 7, 1998

New broad-spectrum anti-MRSA pyrrolidinone cephalosporin and water-soluble prodrug from Roche

Oct. 6, 1998

Abbott obtains new ketolides with improved activity against MLS-resistant strains

Oct. 6, 1998

Lilly glycopeptide advances to phase II for various resistant infections

Oct. 6, 1998

Novel acid-stable macrolides from Abbott presented at ICAAC

Oct. 6, 1998

MiKasome phase I data presented at ICAAC; development update

Oct. 6, 1998

Preclinical profile of BI-397, a promising new glycopeptide antibiotic

Oct. 6, 1998

HMR-3647: the first ketolide to reach advanced-stage clinical testing

Oct. 6, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...